Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRIM59-IFT80 readthrough is a naturally occurring transcript resulting from readthrough between the adjacent TRIM59 and IFT80 genes on chromosome 3. It is classified as a non-coding RNA, and current genomic data indicate it is unlikely to encode a protein product or serve as a receptor, enzyme, transporter, or other classical drug target. There is no evidence for specific biological function or implication in disease roles, drug interactions, or use as a biomarker. Alternative names include IFT80-L and TRIM59-IFT80. Any references to it as a therapeutic target or receptor likely stem from confusion with its parent gene IFT80, which encodes a protein important for ciliary function but is a distinct entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TRIM59-IFT80 readthrough (TRIM59-IFT80).